Health Catalyst (NASDAQ:HCAT) Price Target Lowered to $10.00 at Citigroup

Health Catalyst (NASDAQ:HCAT) had its target price lowered by equities researchers at Citigroup from $10.50 to $10.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price target would indicate a potential upside of 44.09% from the stock’s previous close.

Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada lifted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. Evercore ISI raised their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Finally, KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research note on Wednesday. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Health Catalyst presently has an average rating of “Moderate Buy” and a consensus target price of $11.45.

Health Catalyst Stock Down 5.7 %

NASDAQ HCAT traded down $0.42 during trading hours on Friday, reaching $6.94. 236,109 shares of the company’s stock traded hands, compared to its average volume of 505,904. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The firm has a 50-day simple moving average of $7.81 and a 200 day simple moving average of $7.52. The firm has a market cap of $422.29 million, a PE ratio of -5.14 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same period last year, the firm posted ($0.22) earnings per share. The company’s revenue was up 3.5% compared to the same quarter last year. Sell-side analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

Insider Transactions at Health Catalyst

In other news, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $160,309.76. Following the sale, the general counsel now directly owns 72,250 shares in the company, valued at $601,120. This represents a 21.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the transaction, the insider now owns 236,950 shares in the company, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,342 shares of company stock valued at $554,695. 2.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently modified their holdings of the company. Primecap Management Co. CA grew its holdings in Health Catalyst by 14.7% in the second quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares during the period. Janney Montgomery Scott LLC purchased a new position in Health Catalyst in the third quarter valued at approximately $897,000. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst in the third quarter worth $6,858,000. Millrace Asset Group Inc. purchased a new position in shares of Health Catalyst in the 3rd quarter valued at $1,568,000. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after acquiring an additional 211,805 shares in the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.